Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Intrinsic Value
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ANEB.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Anebulo Pharmaceuticals Inc's business.
What risks and challenges
does Anebulo Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of Anebulo Pharmaceuticals Inc.
Provide P/E
for Anebulo Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
Anebulo Pharmaceuticals Inc
Current Assets | 6.8m |
Cash & Short-Term Investments | 6.6m |
Other Current Assets | 171.7k |
Non-Current Assets | 684.5k |
Other Non-Current Assets | 684.5k |
Current Liabilities | 1m |
Accounts Payable | 318.7k |
Accrued Liabilities | 694.9k |
Earnings Waterfall
Anebulo Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-10.7m
USD
|
Operating Income
|
-10.7m
USD
|
Other Expenses
|
156k
USD
|
Net Income
|
-10.5m
USD
|
Free Cash Flow Analysis
Anebulo Pharmaceuticals Inc
What is Free Cash Flow?
ANEB Profitability Score
Profitability Due Diligence
Anebulo Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Anebulo Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ANEB Solvency Score
Solvency Due Diligence
Anebulo Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Anebulo Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANEB Price Targets Summary
Anebulo Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ANEB is 6.12 USD with a low forecast of 4.04 USD and a high forecast of 8.4 USD.
Ownership
ANEB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ANEB Price
Anebulo Pharmaceuticals Inc
Average Annual Return | -36.34% |
Standard Deviation of Annual Returns | 40.27% |
Max Drawdown | -81% |
Market Capitalization | 74.4m USD |
Shares Outstanding | 25 933 200 |
Percentage of Shares Shorted | 0.08% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The firm's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). The company has completed Phase I trials.